Technology ID
TAB-4349

Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members

E-Numbers
E-100-2020-0
Lead Inventor
Swaroop, Anand (NEI)
Co-Inventors
Shimada-Ishii, Hiroko (NEI)
Chen, Yu Holly (NEI)
English, Milton (NEI)
Applications
Research Materials
Development Stages
Discovery
Lead IC
NEI
ICs
NEI

Approximately one-third of non-syndromic retinal dystrophies involve a defect in a ciliary protein. Non-syndromic retinal ciliopathies include retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis (LCA). Many CEP290-LCA patients also exhibit auditory and olfactory defects. Induced pluripotent stem cells (iPS) cells were derived from patients with LCA and unaffected relatives. 
The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of these iPS cells.

Competitive Advantages:

  • Extensive characterization, including use in making 3-D retinal organoids and optic cup organoids
  • Complement studies with model organisms and examine retinal dystrophies relevant to humans

Commercial Applications:

  • Screening for agents to treat patients with CEP290-associated ciliopathies such as retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis 
Licensing Contact:
Alsaffar, Hiba
hiba.alsaffar@nih.gov